U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07176962) titled 'A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening' on Sept. 10.
Brief Summary: Biliary tract carcinoma (BTC), including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, ranks sixth in incidence among gastrointestinal malignancies and tenth in cancer-related mortality worldwide. Due to the lack of specific early symptoms, high malignancy, and frequent recurrence and metastasis, the rate of curative resection is only about 16.5%, and the overall 5-year survival rate is less than 5%. Early and accurate detection is therefore critical for improving patient outcomes...